Ferring Applauds New Jersey and Michigan for Proclamations Recognizing November as C. Difficile Infection Awareness Month
Parsippany, NJ – November 12, 2025 – Ferring Pharmaceuticals thanks New Jersey and Michigan for recognizing November as Clostridioides difficile (C. diff) Infection Awareness Month. The proclamations raise important awareness of the severe impact of C. diff infection, a serious and potentially deadly infection. This is the sixth consecutive year the office of New Jersey Governor Phil Murphy demonstrated commitment to public health by proclaiming November as C. diff Infection Awareness Month.
To further support C. diff infection education and awareness, the sign on the historic Lower Trenton Bridge in New Jersey – “Trenton Makes The World Takes” – was lit in green from November 12-16. The New Jersey State House Capitol Dome was also lit in green on November 12.
According to the U.S. Centers for Disease Control and Prevention (CDC), C. diff infection remains an urgent public health threat and the most common healthcare-associated infection causing an estimated half a million illnesses and tens of thousands of deaths in the U.S each year.1,2 While healthcare-associated cases of C. diff infection are decreasing, community associated infections are not.1 Strategies to help reduce infection rates include education on responsible antibiotic use, improved cleaning and disinfection in healthcare facilities and infection control measures.1
“We’re grateful for the support of New Jersey and Michigan and their declaration of C. diff Infection Awareness Month,” said Raza Ahmed, MD, Senior Director, Medical Affairs, Ferring Pharmaceuticals. “Continued awareness of the significant toll C. diff takes on patients, families, caregivers and healthcare providers is critical to advancing patient care and helping more people.”
For more information about C. diff infection and to access resources for patients and caregivers, please visit our website.
About C. diff Infection
C. diff infection is a serious and potentially deadly infection that impacts people across the globe. The C. diff bacterium causes debilitating symptoms, such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea and colitis (an inflammation of the colon).2 C. diff infection can be the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system.1,3 It has been estimated that up to 35% of C. diff infection cases recur after initial diagnosis and people who have had a recurrence are at significantly higher risk of further infections.4,5,6,7 After the first recurrence, it has been estimated that up to 65% of patients may develop a subsequent recurrence.6,7 Antibiotics – the current standard of care for treatment of C. diff infection – treat the disease but can also be a contributing factor to the cycle of recurrence.2
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
For more information, please visit www.ferringusa.com, call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn, and X (Twitter).
References:
- Centers for Disease Control and Prevention. 2019 Antibiotic Resistance Threats Report: Clostridioides difficile. 2021 Nov. Available from: https://www.cdc.gov/antimicrobialresistance/media/pdfs/clostridioides-difficile-508.pdf
- Centers for Disease Control and Prevention. What is diff? 2022 Sep. Available from: https://www.cdc.gov/c-diff/about/
- Feuerstadt P, et al. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J Med Econ. 2020 Jun.;23(6):603-609. Available from: https://pubmed.ncbi.nlm.nih.gov/31999199/
- Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009 Sept.;23(3):727-743. Available from: https://pubmed.ncbi.nlm.nih.gov/19665092/
- Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. 2021 Jul.;27(7):828-838. Available from: https://pubmed.ncbi.nlm.nih.gov/33703939/
- Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012 Dec.;18(Suppl. 6):21–27. Available from:https://pubmed.ncbi.nlm.nih.gov/23121551/
- Smits WK, et al. Clostridium difficile Nat Rev Dis Primers. 2016 Apr.;2:16020. Available from: https://pubmed.ncbi.nlm.nih.gov/27158839/
# # #
For more information, please contact
Patrick Gorman
Senior Director, Corporate Communications
(862) 286-5035 (direct)
(973) 722-6335 (mobile)
patrick.gorman@ferring.com